In Vitro and in Vivo Pharmacodynamics of Three Novel Antileishmanial Lead Series

Overview

Journal Int J Parasitol Drugs Drug Resist

Publisher Elsevier

Specialty Parasitology

Date 2018 Feb 10

PMID 29425734

Citations 24

Authors

M van den Kerkhof

D Mabille

E Chatelain

C E Mowbray

S Braillard

S Hendrickx

L Maes

G Caljon

Affiliations

Soon will be listed here.

Abstract

Objectives: Three new chemical series (bicyclic nitroimidazoles, aminopyrazoles and oxaboroles) were selected by Drugs for Neglected Diseases initiative as potential new drug leads for leishmaniasis. Pharmacodynamics studies included both in vitro and in vivo efficacy, cross-resistance profiling against the current antileishmanial reference drugs and evaluation of their cidal activity potential.

Methods: Efficacy against the reference laboratory strains of Leishmania infantum (MHOM/MA(BE)/67/ITMAP263) and L. donovani (MHOM/ET/67/L82) was evaluated in vitro on intracellular amastigotes and in vivo in the early curative hamster model. Cidal activity was assessed over a period of 15 days in an in vitro 'time-to-kill' assay. Cross-resistance was assessed in vitro on a panel of L. infantum strains with different degrees of resistance to either antimony, miltefosine or paromomycin.

Results: All lead compounds showed potent and selective in vitro activity against the Leishmania strains tested and no cross-resistance could be demonstrated against any of the current antileishmanial drugs. Cidal activity was obtained in vitro for all series within 15 days of exposure with some differences noted between L. donovani and L. infantum. When evaluated in vivo, all lead compounds showed high efficacy and no adverse effects were observed.

Conclusions: The new lead series were shown to have cidal pharmacodynamic activity. The absence of cross-resistance with any of the current antileishmanial drugs opens possibilities for combination treatment to reduce the likelihood of treatment failures and drug resistance.

Citing Articles

Synthesis and in vitro antitrypanosomatid activity of novel 5-nitroindole-rhodanine conjugates.

Badenhorst E, Aucamp J, Kannigadu C, Janse van Rensburg H, Suganuma K, NDa D Future Med Chem. 2025; 17(5):557-573.

PMID: 39995114 PMC: 11901381. DOI: 10.1080/17568919.2025.2470110.

Bioluminescence Imaging Reveals Differences in Parasite Killing Kinetics by Antileishmanial Reference Drugs.

Hendrickx S, Feijens P, Escudie F, Chatelain E, Maes L, Caljon G ACS Infect Dis. 2024; 10(6):2101-2107.

PMID: 38733389 PMC: 11423396. DOI: 10.1021/acsinfecdis.4c00109.

Practical Synthesis of 6-Amino-1-hydroxy-2,1-benzoxaborolane: A Key Intermediate of DNDI-6148.

Khairnar P, Saathoff J, Cook D, Hochstetler S, Pandya U, Robinson S Org Process Res Dev. 2024; 28(4):1213-1223.

PMID: 38660377 PMC: 11036395. DOI: 10.1021/acs.oprd.4c00031.

Further Investigations of Nitroheterocyclic Compounds as Potential Antikinetoplastid Drug Candidates.

Garcia-Estrada C, Perez-Pertejo Y, Dominguez-Asenjo B, Holanda V, Murugesan S, Martinez-Valladares M Biomolecules. 2023; 13(4).

PMID: 37189384 PMC: 10136037. DOI: 10.3390/biom13040637.

A QSAR Study for Antileishmanial 2-Phenyl-2,3-dihydrobenzofurans .

Bernal F, Schmidt T Molecules. 2023; 28(8).

PMID: 37110632 PMC: 10144340. DOI: 10.3390/molecules28083399.

References

Pevarello P, Brasca M, Amici R, Orsini P, Traquandi G, Corti L . 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding. J Med Chem. 2004; 47(13):3367-80. DOI: 10.1021/jm031145u. View

Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, Arnold U . Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet. 2009; 374(9683):56-64. DOI: 10.1016/S0140-6736(09)61117-X. View

Bahia M, Andrade I, Martins T, Nascimento A, de Figueiredo Diniz L, Caldas I . Fexinidazole: a potential new drug candidate for Chagas disease. PLoS Negl Trop Dis. 2012; 6(11):e1870. PMC: 3486905. DOI: 10.1371/journal.pntd.0001870. View

Rock F, Mao W, Yaremchuk A, Tukalo M, Crepin T, Zhou H . An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science. 2007; 316(5832):1759-61. DOI: 10.1126/science.1142189. View

De Rycker M, ONeill S, Joshi D, Campbell L, Gray D, Fairlamb A . A static-cidal assay for Trypanosoma brucei to aid hit prioritisation for progression into drug discovery programmes. PLoS Negl Trop Dis. 2012; 6(11):e1932. PMC: 3510075. DOI: 10.1371/journal.pntd.0001932. View

Croft S, Olliaro P . Leishmaniasis chemotherapy--challenges and opportunities. Clin Microbiol Infect. 2011; 17(10):1478-83. DOI: 10.1111/j.1469-0691.2011.03630.x. View

Hendrickx S, van den Kerkhof M, Mabille D, Cos P, Delputte P, Maes L . Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum. PLoS Negl Trop Dis. 2017; 11(5):e0005620. PMC: 5444850. DOI: 10.1371/journal.pntd.0005620. View

Cojean S, Houze S, Haouchine D, Huteau F, Lariven S, Hubert V . Leishmania resistance to miltefosine associated with genetic marker. Emerg Infect Dis. 2012; 18(4):704-6. PMC: 3309694. DOI: 10.3201/eid1804.110841. View

Hendrickx S, Boulet G, Mondelaers A, Dujardin J, Rijal S, Lachaud L . Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum. Parasitol Res. 2014; 113(5):1875-81. DOI: 10.1007/s00436-014-3835-7. View

10.

Fortin A, Hendrickx S, Yardley V, Cos P, Jansen H, Maes L . Efficacy and tolerability of oleylphosphocholine (OlPC) in a laboratory model of visceral leishmaniasis. J Antimicrob Chemother. 2012; 67(11):2707-12. DOI: 10.1093/jac/dks273. View

11.

Sundar S, Olliaro P . Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management. Ther Clin Risk Manag. 2008; 3(5):733-40. PMC: 2376078. View

12.

Sundar S, Singh A . Recent developments and future prospects in the treatment of visceral leishmaniasis. Ther Adv Infect Dis. 2016; 3(3-4):98-109. PMC: 4971590. DOI: 10.1177/2049936116646063. View

13.

Hendrickx S, Eberhardt E, Mondelaers A, Rijal S, Bhattarai N, Dujardin J . Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome. J Antimicrob Chemother. 2015; 70(11):3023-6. DOI: 10.1093/jac/dkv237. View

14.

Tiuman T, Santos A, Ueda-Nakamura T, Dias Filho B, Nakamura C . Recent advances in leishmaniasis treatment. Int J Infect Dis. 2011; 15(8):e525-32. DOI: 10.1016/j.ijid.2011.03.021. View

15.

Motyl M, Dorso K, Barrett J, Giacobbe R . Basic microbiological techniques used in antibacterial drug discovery. Curr Protoc Pharmacol. 2011; Chapter 13:Unit13A.3. DOI: 10.1002/0471141755.ph13a03s31. View

16.

Raju H, Chandrappa S, Prasanna D, Ananda H, Nagamani T, Byregowda S . Synthesis, characterization and in-vitro antiproliferative effects of novel 5-amino pyrazole derivatives against breast cancer cell lines. Recent Pat Anticancer Drug Discov. 2011; 6(2):186-95. DOI: 10.2174/157489211795328459. View

17.

Nare B, Wring S, Bacchi C, Beaudet B, Bowling T, Brun R . Discovery of novel orally bioavailable oxaborole 6-carboxamides that demonstrate cure in a murine model of late-stage central nervous system african trypanosomiasis. Antimicrob Agents Chemother. 2010; 54(10):4379-88. PMC: 2944573. DOI: 10.1128/AAC.00498-10. View

18.

Patterson S, Wyllie S . Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects. Trends Parasitol. 2014; 30(6):289-98. PMC: 4045206. DOI: 10.1016/j.pt.2014.04.003. View

19.

Jacobs R, Nare B, Wring S, Orr M, Chen D, Sligar J . SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl Trop Dis. 2011; 5(6):e1151. PMC: 3125149. DOI: 10.1371/journal.pntd.0001151. View

20.

Wring S, Gaukel E, Nare B, Jacobs R, Beaudet B, Bowling T . Pharmacokinetics and pharmacodynamics utilizing unbound target tissue exposure as part of a disposition-based rationale for lead optimization of benzoxaboroles in the treatment of Stage 2 Human African Trypanosomiasis. Parasitology. 2013; 141(1):104-18. PMC: 3884839. DOI: 10.1017/S003118201300098X. View